Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Myriad Genetics's Enterprise Value is €574.1 Mil.
Myriad Genetics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-334.2 Mil. Therefore, Myriad Genetics's EV-to-EBIT ratio for today is -1.72.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Myriad Genetics's Enterprise Value is €574.1 Mil.
Myriad Genetics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-289.7 Mil. Therefore, Myriad Genetics's EV-to-EBITDA ratio for today is -1.98.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Myriad Genetics's Enterprise Value is €574.1 Mil.
Myriad Genetics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €712.5 Mil. Therefore, Myriad Genetics's EV-to-Revenue ratio for today is 0.81.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Myriad Genetics's Enterprise Value is €574.1 Mil.
Myriad Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-20.4 Mil. Therefore, Myriad Genetics's EV-to-FCF ratio for today is -28.21.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Myriad Genetics (STU:MYD) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Myriad Genetics's current Enterprise Value is €574.1 Mil.
Myriad Genetics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-334.2 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Myriad Genetics's current Enterprise Value is €574.1 Mil.
Myriad Genetics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-289.7 Mil.
Myriad Genetics's current Enterprise Value is €574.1 Mil.
Myriad Genetics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €712.5 Mil.
Myriad Genetics's current Enterprise Value is €574.1 Mil.
Myriad Genetics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.7 Mil.
Myriad Genetics's current Enterprise Value is €574.1 Mil.
Myriad Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-20.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics Enterprise Value Related Terms
Myriad Genetics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Myriad Genetics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Enterprise Value of €574.1 Mil as of Jul. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Enterprise Value too high?
Myriad Genetics' current Enterprise Value is €574.1 Mil. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Enterprise Value compare to FLGT and CSTL?
Myriad Genetics' Enterprise Value of €574.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Enterprise Value is €574.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.15, compared to a current price of €5.20 — trading 60.4% below its estimated fair value. The current Enterprise Value is €574.1 Mil. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Enterprise Value is €574.1 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €5.20 is trading 60.4% below its estimated GF Value™ of €13.15.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Enterprise Value: €574.1 Mil
GF Value™: €13.15 vs. price of €5.20 (60.4% below fair value)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score
Get the complete analysis for STU:MYD
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
